$CYDY It is about CCR5 as a master regulator of tissue injury and repair.
That’s why fibrosis, oncology, HIV, neuroinflammation, long COVID, and autoimmune disease all show signals with CCR5 blockade. This is what makes leronlimab a platform, not a single‑indication drug.
Gir some!
$CYDY
With the standard fourth-line backbone of Lonsurf (trifluridine/tipiracil) plus bevacizumab alone, the expected two-week change in ctDNA is typically 0% to a minor fluctuation, rather than a true decline
$CYDY heres what my ai said. 2part
While the combination of Lonsurf (trifluridine/tipiracil) and bevacizumab (Avastin) is a highly effective, FDA-approved standard for metastatic colorectal cancer (mCRC), rapid two-week drops in circulating tumor DNA (ctDNA) are not typically seen with this combination alone.
Substantial early ctDNA declines (e.g., a median 70% drop at week 2) have only been recently reported in clinical trials testing this backbone alongside investigational agents, such as the CCR5-inhibitor leronlimab (the CLOVER trial).
$CYDY Let me get this straight. ALL OF OUR 3rd LINE CRC PATIENTS HAD A DROP IN THEIR ctDNA BY WEEK 2‼️And ctDNA is the biomarker that oncologists have started using for early detection of treatment efficacy? And our lead investigator happens to be a leading expert in ctDNA and an advisor to Natera?
I think we’re at the right place at the right time‼️
